Protagonist Therapeutics Q2 2024 GAAP EPS $(0.50) Beats $(0.69) Estimate
Portfolio Pulse from Benzinga Newsdesk
Protagonist Therapeutics (NASDAQ:PTGX) reported a Q2 2024 GAAP EPS of $(0.50), beating the analyst consensus estimate of $(0.69) by 27.54%. This represents a 26.47% improvement over the $(0.68) loss per share from the same period last year.
August 06, 2024 | 11:52 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Protagonist Therapeutics reported a Q2 2024 GAAP EPS of $(0.50), beating estimates by 27.54% and showing a 26.47% improvement from last year. This positive earnings surprise is likely to boost investor confidence and positively impact the stock price in the short term.
The better-than-expected earnings report indicates improved financial performance, which is likely to boost investor sentiment and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100